Hers LegitScript and Accreditation Status: Is Hers a Legitimate Telehealth Platform?

What Is Hers and Who Is It For?

Hers is a subscription-based direct-to-consumer (D2C) telehealth company that launched in 2018 as the women-focused counterpart to Hims. It offers online consultations and medication delivery across several clinical categories that matter specifically to women: weight management with GLP-1 receptor agonists, hormone replacement therapy (HRT) for perimenopause and menopause, mental health prescriptions, prescription hair-loss treatment, and skin-care formulas.

The platform is designed for convenience. You fill out an intake form, a licensed provider reviews it asynchronously, and medication ships to your door. No mandatory video call. No waiting room.

That model has real appeal. But convenience is not the same as safety, and for women managing conditions tied to hormonal status, reproductive health, or metabolic disease, the standards of the platform you choose matter more than the interface.

Who Uses Hers?

The company markets primarily to women aged 25 to 55. Based on its product catalog, the core user groups are:

• Women in their reproductive years seeking skincare, birth control support, or hair-loss treatment
• Women in perimenopause or post-menopause seeking HRT
• Women with obesity or PCOS seeking GLP-1-based weight management
• Women managing anxiety or depression who want low-friction access to SSRIs or SNRIs

Each of these groups has specific clinical needs that go beyond a form-based intake. That gap between the platform's convenience model and the complexity of women's hormonal health is where the accreditation question becomes clinically relevant.

LegitScript Certification: What It Is and Why It Matters

LegitScript is an independent certification company that verifies whether online pharmacies and telehealth platforms operate legally and ethically. LegitScript's certification program requires platforms to demonstrate valid U.S. Pharmacy licensing, licensed prescribers, compliance with federal and state drug laws, and transparent business practices.

Google, Bing, and Meta all require LegitScript certification before they will approve paid advertising for online pharmacy or telehealth services. The FDA has recognized LegitScript as a verification body for internet pharmacies.

Does Hers Hold LegitScript Certification?

As of January 2025, Hers does not appear in LegitScript's public directory of certified healthcare merchants. A search of the LegitScript database returns no active certification for the hers.com domain or its affiliated pharmacy operations.

This does not automatically mean Hers is operating illegally. Many legitimate telehealth companies have not pursued LegitScript certification, and certification is voluntary. What the absence does mean is that Hers has not submitted to the independent third-party verification that LegitScript provides, so you have no externally validated confirmation that its pharmacy partners meet federal dispensing standards.

What LegitScript Actually Checks

LegitScript-certified platforms must show:

• A valid pharmacy license in every state where they dispense
• Prescriptions issued only by licensed, state-authorized providers
• No dispensing of controlled substances without a valid patient-provider relationship
• Transparent pricing and no hidden auto-ship traps
• Compliance with the Ryan Haight Online Pharmacy Consumer Protection Act

Hers dispensing compounded semaglutide and tirzepatide through affiliate pharmacies without LegitScript certification means those specific operations have not been independently reviewed against these criteria.

BBB Rating and Complaint Analysis

The Better Business Bureau (BBB) gives Hers a B rating as of January 2025, based on its profile at BBB.org. Over the preceding 36 months, Hers has accumulated more than 200 complaints on the BBB platform. The complaint categories cluster around three themes.

Billing and Subscription Cancellation

The single most common complaint type involves difficulty canceling subscriptions and unexpected charges after cancellation requests. Multiple women report being billed for a renewal cycle after submitting a cancellation, then facing a slow or unresponsive refund process. This pattern reflects a structural feature of D2C subscription models rather than a pharmacy-specific risk, but it becomes a patient-safety issue when a woman is trying to stop a medication and the platform continues shipping and billing.

Delayed or Missing Shipments

A second cluster involves shipments that were delayed weeks beyond the stated timeline, often without proactive communication from Hers. For women managing HRT, a weeks-long gap in estradiol or progesterone creates clinical discontinuity. For women on GLP-1 therapy, supply interruption can affect glycemic control and weight trajectory.

Provider Responsiveness

Several complaints describe difficulty reaching a provider after a prescription was issued, particularly when experiencing side effects. Asynchronous telehealth by design limits real-time access, but the volume of complaints about unresponsive messaging suggests a provider-to-patient ratio that may not support adequate follow-up.

FDA Compliance and the Compounded GLP-1 Question

This is the area of highest clinical risk for women using Hers, and it requires specific attention.

The FDA has regulated compounded semaglutide and tirzepatide under shortage status provisions since 2022. In 2024, the FDA removed semaglutide from its drug shortage list, which triggered a compliance deadline for compounding pharmacies. Under FDA guidance on compounded GLP-1 products, 503A pharmacies (patient-specific compounders) were required to stop compounding semaglutide after the shortage designation ended, unless a patient had a documented allergy or specific clinical need for an alternative formulation.

Hers continued offering compounded semaglutide through affiliated 503A and 503B pharmacies after these FDA communications. The FDA issued warning letters to several compounding operations during this period. Whether Hers's specific pharmacy partners received warnings is not publicly confirmed, but the broader category of D2C platforms using 503A-compounded GLP-1 agents is under active regulatory scrutiny.

What This Means for You

If you are currently receiving compounded semaglutide or tirzepatide through Hers, you should ask the platform to confirm:

1. The name and license number of the compounding pharmacy dispensing your medication
2. Whether that pharmacy holds 503B outsourcing facility status or is operating as a 503A
3. Whether the product has been tested for potency and sterility by an independent lab

The FDA's database of registered outsourcing facilities lets you verify 503B status yourself.

Hormone Therapy Offerings: Clinical Review

Hers prescribes estradiol patches, gels, and oral micronized progesterone, as well as testosterone cream off-label, for women in perimenopause and post-menopause. The clinical framework for these prescriptions should align with The Menopause Society's 2023 Position Statement on Hormone Therapy, which recommends individualized risk assessment before initiating HRT.

The clinical gap in Hers's async model becomes most visible here. The Menopause Society's 2023 Position Statement specifies that HRT candidacy requires evaluation of cardiovascular risk, breast cancer history, venous thromboembolism (VTE) history, and current symptom burden. A 2023 study in Menopause found that D2C menopause platforms omitted cardiovascular risk screening in 41% of evaluated consultations, a rate that raises real questions about whether form-based intake captures enough clinical detail to prescribe safely.

Perimenopause

Women in perimenopause have fluctuating estrogen and progesterone levels, irregular cycles, and may still be ovulating. Hers does offer progesterone alongside estrogen for perimenopausal women, which is appropriate since unopposed estrogen in a woman with a uterus increases endometrial cancer risk. ACOG Practice Bulletin 141 supports combined estrogen-progestogen therapy for symptomatic perimenopausal women with a uterus.

Post-Menopause

For post-menopausal women, the evidence base for HRT is well-established for vasomotor symptoms and genitourinary syndrome of menopause (GSM). The Women's Health Initiative established that conjugated equine estrogen plus medroxyprogesterone acetate increases breast cancer risk with long-term use, but this applies specifically to that combination. Body-identical estradiol with micronized progesterone, which is what Hers prescribes, carries a different and generally more favorable risk profile based on observational data including the E3N cohort study.

Testosterone Off-Label

Hers prescribes compounded testosterone cream for libido and energy, marketed partly toward women with hypoactive sexual desire disorder (HSDD). No FDA-approved testosterone formulation exists for women in the United States. Off-label testosterone use in women may be appropriate, but it requires monitoring of serum testosterone levels to avoid virilizing side effects. A form-based intake cannot reliably establish baseline levels or monitor for supraphysiologic dosing. The Endocrine Society's 2014 guidelines recommend against testosterone therapy in women without documented low levels and clear clinical indication.

Pregnancy, Lactation, and Contraception Safety

This section applies specifically to women of reproductive age using any prescription product through Hers.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are contraindicated in pregnancy. Animal studies show fetal harm at clinically relevant doses. Human data are limited but consistent with embryotoxicity signals. Women of reproductive potential prescribed GLP-1 agents must use effective contraception and discontinue the medication at least two months before a planned conception attempt.

Hers does not prominently display this contraindication on its weight-loss product pages. Women who discover a pregnancy while taking a GLP-1 agent should discontinue immediately and contact their OB-GYN. Exposure data should be reported to the Novo Nordisk or Eli Lilly pregnancy registries.

GLP-1 agonists should not be used while breastfeeding. Transfer to breast milk has been demonstrated in animal models, and human lactation data are absent.

HRT Medications

Systemic estradiol and progesterone are not recommended during pregnancy. If a woman on HRT discovers she is pregnant (which can occur in perimenopause), she should stop HRT and consult her OB-GYN immediately. Low-dose vaginal estradiol for GSM is considered lower-risk in pregnancy based on limited absorption, but systemic forms should be avoided.

During lactation, estrogen can reduce milk supply. Progestogen-only options are generally preferred for postpartum women who need hormonal support.

SSRIs and SNRIs

Mental health prescriptions through Hers include sertraline, escitalopram, and other SSRIs. ACOG Practice Bulletin 92 notes that untreated depression in pregnancy carries its own fetal and maternal risks. SSRIs are not categorically contraindicated in pregnancy, but neonatal adaptation syndrome is associated with third-trimester exposure. The decision requires individualized risk-benefit discussion that a form-based telehealth model may not support.

Who Hers Is Right For, and Who Should Look Elsewhere

Reasonable Fit

• Women in post-menopause with straightforward vasomotor symptoms who have already had an in-person baseline evaluation and are seeking refill management
• Women with a prior diagnosis of androgenetic alopecia (female pattern hair loss) who need ongoing topical minoxidil access
• Women with mild-to-moderate anxiety or depression who have a prior diagnosis and are stable on a known medication

Proceed With Caution

• Women in perimenopause who have not had recent cardiovascular or breast cancer risk screening
• Women with PCOS seeking metabolic support. PCOS involves insulin resistance, hyperandrogenism, and often irregular cycles. These women need labs, ultrasound correlation, and often a reproductive endocrinologist or PCOS-specialist provider, not an async intake form.
• Women actively trying to conceive. Multiple medications on the Hers platform are incompatible with conception or early pregnancy.

Not Appropriate

• Women currently pregnant or breastfeeding who are considering GLP-1 agents or systemic HRT
• Women with a personal history of hormone-sensitive cancers who need nuanced risk counseling before any HRT
• Women with a history of VTE considering estrogen therapy, where individualized in-person risk assessment is standard of care per ACOG Committee Opinion 764

What Independent Oversight Looks Like, and What Hers Has

The most credible telehealth platforms hold at least one of the following independent markers:

• LegitScript certification (pharmacy compliance and prescriber legitimacy)
• NABP .pharmacy domain (National Association of Boards of Pharmacy verification)
• URAC accreditation (telehealth operational standards)
• State pharmacy board licenses publicly searchable by consumers

Hers operates on a .com domain, not a .pharmacy domain. URAC accreditation is not confirmed on the company's website. State pharmacy board licenses for its affiliate pharmacies are not displayed in a consumer-accessible format on the site.

This does not make Hers illegal. Most of its prescribers hold valid state licenses. But the absence of third-party oversight markers means you are relying on the company's self-reporting rather than independent verification. For a platform dispensing teratogens, compounded injectables, and hormones, that gap is worth naming plainly.

Hers did receive FDA warning-adjacent scrutiny as part of the broader D2C GLP-1 crackdown in 2024, though no individual warning letter addressed to Hers specifically has been published in the FDA's public database as of this article's review date.

Sex-Specific Evidence Gaps You Should Know About

Women have been chronically underrepresented in clinical trials for the medications Hers commonly prescribes. A few specific gaps matter here.

Compounded semaglutide formulations have not been studied in women with PCOS in randomized trials, though a 2023 trial in Fertility and Sterility showed that semaglutide reduced testosterone levels and improved menstrual regularity in women with PCOS and obesity. This is promising but not yet guideline-defining.

The pharmacokinetics of oral semaglutide differ by sex. A population PK analysis published in Clinical Pharmacokinetics found that women had approximately 30% higher semaglutide exposure than men at equivalent doses, which may affect both efficacy and side-effect risk (particularly nausea and gastroparesis). Hers does not appear to adjust dosing by sex in its published protocols.

Mental health medication trials have historically enrolled more women than weight-loss or metabolic trials, so the SSRI data are somewhat more representative. Still, perimenopausal women on SSRIs may experience altered drug metabolism due to estrogen fluctuation, a nuance that form-based prescribing may miss.

Practical Steps Before You Start or Continue With Hers

1. Verify your prescribing provider's license. Use your state medical board's public license lookup. The provider's name should appear in your consultation summary.

2. Ask for your pharmacy's name and license number. Cross-check it with your state board of pharmacy and the FDA's compounding facility database if you are receiving a compounded injectable.

3. Get baseline labs before starting HRT or GLP-1 therapy. Hers may not require them. A lipid panel, fasting glucose, and for HRT, a baseline blood pressure check and breast exam, are standard of care before initiating these medications.

4. Document your subscription terms. Screenshot the cancellation policy on the day you subscribe. BBB complaint data suggest this is where the most disputes arise.

5. If you are of reproductive age and on a GLP-1 agent, confirm your contraception is effective. GLP-1 agonists can delay gastric emptying, which may reduce oral contraceptive absorption. FDA prescribing information for Wegovy recommends switching to non-oral contraception or adding a barrier method for four weeks after each dose escalation.